Related Experiment Video
Updated: May 26, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Wogonin-Loaded PLGA Sustained-Release Nanomicelle Inhibiting EGFR Pathway for Antitumor Effects in OSCC
Leina Gao1, Dixin Cui1, Xu Gao1
1Qingdao Stomatological Hospital Affiliated to Qingdao University, Qingdao 266001, China.
Abstract:
Oral squamous cell carcinoma (OSCC) is the most prevalent malignancy of the head and neck. Current treatment strategies, including surgery, radiotherapy, and chemotherapy, are limited by moderate efficacy and severe side effects, highlighting the need for novel therapeutic approaches. Wogonin (Wo), a natural flavonoid, has shown antiproliferative, pro-apoptotic, and antimetastatic activities in various cancer models; however, its effect on OSCC has not been investigated. In this study, Wo-loaded poly-(lactic-co-glycolic acid) nanoparticles (PW NPs) were prepared to enhance water solubility and achieve sustained drug release. In vitro assays, including CCK-8, flow cytometry, live/dead staining, and wound healing assays, revealed that PW NPs significantly inhibited OSCC cell proliferation, induced apoptosis, and reduced cell migration. Network pharmacology analysis and qRT-PCR further suggested that Wo exerts its therapeutic effects through the EGFR signaling pathway. Hemolysis testing and histological examination of major organs confirmed the favorable biocompatibility of the nanoparticles. This study provides the first systematic evidence of the therapeutic potential of Wo in OSCC and lays a foundation for its further preclinical development.
Insights
Wogonin nanoparticles show promise for treating oral squamous cell carcinoma (OSCC). This study demonstrates their ability to inhibit cancer cell growth, induce apoptosis, and reduce migration, offering a potential new therapy for OSCC.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Oral squamous cell carcinoma (OSCC) is a common head and neck cancer with limited treatment options.
- Current therapies for OSCC have moderate efficacy and significant side effects.
- Novel therapeutic strategies are needed for OSCC treatment.
Purpose of the Study:
- To investigate the therapeutic potential of Wogonin (Wo) in oral squamous cell carcinoma (OSCC).
- To develop and evaluate Wogonin-loaded poly-(lactic-co-glycolic acid) nanoparticles (PW NPs) for enhanced delivery and sustained release.
- To explore the underlying mechanisms of Wogonin's action in OSCC.
Main Methods:
- Preparation and characterization of Wogonin-loaded poly-(lactic-co-glycolic acid) nanoparticles (PW NPs).
- In vitro evaluation of PW NPs effects on OSCC cell proliferation, apoptosis, and migration using CCK-8, flow cytometry, live/dead staining, and wound healing assays.
- Network pharmacology analysis and qRT-PCR to identify the signaling pathway involved.
- Biocompatibility assessment through hemolysis testing and histological examination.
Main Results:
- PW NPs effectively inhibited OSCC cell proliferation and migration in vitro.
- PW NPs significantly induced apoptosis in OSCC cells.
- Network pharmacology and qRT-PCR indicated that Wogonin targets the EGFR signaling pathway.
- Hemolysis testing and organ histology confirmed the favorable biocompatibility of PW NPs.
Conclusions:
- Wogonin, delivered via nanoparticles, demonstrates significant therapeutic potential against oral squamous cell carcinoma.
- PW NPs offer a promising approach for OSCC treatment due to enhanced efficacy and favorable biocompatibility.
- This study provides a foundation for the preclinical development of Wogonin-based therapies for OSCC.
